3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment

US11045449B2 · kind B2 · utility

Assignees

• Johannes Gutenberg-Universität Mainz · DE
• Universitätsmedizin der Johannes Gutenberg-Universität Mainz · DE

Inventors

• Markus Möhler · Mainz, DE
• Annett Maderer · Griesheim, DE
• Gerd Dannhardt · Mainz, DE
• Christopher Ganser · Mainz, DE
• Eva Lauermann · Mainz, DE
• René Mönnikes · Mainz, DE

Key dates

• Filing date: Dec 28, 2016
• Grant date: Jun 29, 2021
• Expiry date: Dec 28, 2036

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to 3-(5-fluoroindolyl)-4-arylmaleimide compounds and pharmaceutical compositions containing them. The compounds of the present invention are protein kinases (GSK-3beta, VEGFR-2 and FLT-3) with antineoplastic activity. They can therefore be used for the treatment or prevention of tumors, in particular solid tumors.